NDA Industry Insight: A new dawn in regulation and access
Mel Walker, Advisory Board Member at NDA, explains: “ILAP is unique in that it brings the HTA, the payer, and the regulator together at a much earlier stage in a products development when the entire clinical plan can be influenced in a way that is not possible when a product is further down the development pathway. By going early and involving all the right stakeholders, the chances of the product ultimately getting to patients, not just getting approved, can be maximised. It’s a classic case of starting with the end in mind and companies should take a close look at this offering when developing early commercial strategy.”
Written by Dr. Ingela Loell, Scientific Writer at NDA Group